Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23146200 | 0.80 | TDP1 (0.38) | TDP1ALDH1A1KDM4EKCNJ1MAPT | |
| SCHEMBL4892445 | 0.80 | — | — | |
| SCHEMBL3765228 | 0.77 | ALDH1A1 (0.37) | TDP1ALDH1A1KDM4EKCNJ1MAPT | |
| SCHEMBL16935016 | 0.77 | ALDH1A1 (0.37) | TDP1ALDH1A1KDM4EKCNJ1MAPT | |
| SCHEMBL23146412 | 0.76 | ALDH1A1 (0.42) | TDP1ALDH1A1KDM4EACACBCYP2C9 | |
| SCHEMBL1620284 | 0.73 | ACACB (0.43) | TDP1ALDH1A1KDM4EACACBCYP2C9 | |
| SCHEMBL29237721 | 0.73 | ACACB (0.37) | TDP1ALDH1A1KDM4EACACBCYP2C9 | |
| SCHEMBL4538013 | 0.73 | DUT (0.36) | TDP1ALDH1A1KDM4EKCNJ1 | |
| SCHEMBL15889359 | 0.72 | — | — | |
| SCHEMBL14347621 | 0.72 | CDC7 (0.42) | ALDH1A1KDM4ECYP2C9MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| EP-3810595-A1 | OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112334462-A | OGA inhibitor compounds | 詹森药业有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2019243531-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-20180009796-A1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-01-11 | — | — | US | disclosed |
| US-6372913-B1 | REACTING HALOGENOMALONALDEHYDE WITH THIOCARBAMATE OR DITHIOCARBAMATE IN PRESENCE OF SOLVENT, WHEREIN REACTION MIXTURE COMPRISES LESS THAN 5% BY WEIGHT, BASED ON TOTAL WEIGHT OF SOLVENT, OF WATER | BAYER AG (DE) | 2002-04-16 | — | — | US | disclosed |
| EP-0896962-A1 | Process for the preparation of 2-substituted-5-formylthiazoles | BAYER AG (DE) | 1999-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009796-A1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MGAT2, MGAT1, ACAT2 | TDP1 3519/4885ALDH1A1 663/4885KDM4E 3767/4885 |
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | TDP1 83/4885ALDH1A1 3839/4885KDM4E 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.